Elevated circulating magnesium levels in patients with Parkinson’s disease: a meta-analysis
Authors Jin X, Liu MY, Zhang DF, Gao H, Wei MJ
Received 2 September 2018
Accepted for publication 15 October 2018
Published 19 November 2018 Volume 2018:14 Pages 3159—3168
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yuping Ning
Xin Jin,1 Ming-Yan Liu,2 Dong-Fang Zhang,1 Hua Gao,3 Min-Jie Wei2,4
1School of Pharmacy, Department of Pharmacognosy, China Medical University, Shenyang, Liaoning, China; 2School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning, China; 3Division of Pharmacology Laboratory, National Institutes for Food and Drug Control, Beijing, China; 4Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Shenyang, Liaoning, China
Background: The association between circulating magnesium (Mg) and Parkinson’s disease (PD) remains ambiguous and controversial. Thus, a meta-analysis was conducted to evaluate the circulating Mg levels in PD patients and to clarify whether high circulating Mg levels should be considered as a potential risk factor for PD.
Methods: In this study, 17 case–control published studies were selected in our meta-analysis by searching the electronic databases of Web of Science, PubMed, and China National Knowledge Infrastructure (CNKI) before June 1, 2018. Overall, 848 PD cases and 784 healthy controls (HC), 1,023 PD cases and 911 HC, and 180 PD cases and 144 HC met the inclusion criteria for this study Mg levels in serum, peripheral blood, and cerebrospinal fluid (CSF), respectively. Standardized mean difference (SMD) in random-effects model and 95% CI were used to assess the correlation strength through the comparison of the two groups.
Results: Meta-analysis showed that the serum Mg levels in PD cases were significantly higher than those in HC individuals (SMD =1.09, 95% CI =0.52, 1.66). Furthermore, this result was further confirmed by the combined analysis of serum and whole blood studies together (SMD =0.64, 95% CI =0.10, 1.19). In addition, the higher CSF Mg levels in patients of PD were observed in comparison with normal range (SMD =0.55, 95% CI =0.21, 0.88). However, this data did not further discuss and analyze because of the smaller sample size of CSF studies.
Conclusion: Our findings supported the notion that the increase of circulating Mg levels appears in the patients with PD.
Keywords: magnesium, serum, peripheral blood, CSF, Parkinson’s disease, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]